Trial Profile
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Coronary artery disease; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms LIGHT
- Sponsors Pfizer
- 04 Jan 2012 Actual patient number is 758 according to ClinicalTrials.gov.
- 04 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.